U.S. stock night trading volatility: Executive buybacks failed to boost confidence, Aprea Therapeutics fell 5.88% in after-hours trading due to market sentiment drag

U.S. Stock Night Market Movements Aprea Therapeutics fell 5.88% in the night market. Based on recent key news: On February 2, Aprea Therapeutics' Chief Financial Officer John P. Hamill reported the acquisition of the company's common stock. This move may be interpreted by the market as confidence in the company's future development, but it failed to prevent the stock price from falling. On February 2, Aprea Therapeutics' President and CEO Gilad Oren also reported the acquisition of common stock. Although executive purchases are usually seen as a positive signal, the market's reaction remained negative, leading to a decline in stock price. On February 2, Recce Pharmaceuticals signed a second research and development agreement with the U.S. Department of Defense to promote the research of Recce 327 gel for burn wounds. Although this event is not directly related to Aprea Therapeutics, it may affect the overall sentiment in the biopharmaceutical industry. The biopharmaceutical industry has seen increased volatility recently and requires attention. Stocks with High Trading Volume in the Industry Recursion rose 0.98% in the night market. Based on recent key news: On February 4, OpenAI's CEO Altman stated that the company may seek partners or investments in AI drug discovery. This news has drawn market attention to Recursion Pharmaceuticals, driving its stock price up. There is significant potential for collaboration in the AI drug sector. ImmunityBio fell 0.32% in the night market. Based on recent key news: On February 2, ImmunityBio announced the initiation of the second phase clinical trial of ResQ215B, evaluating its CD19 t-haNK cell therapy in combination with Anktiva and rituximab for indolent non-Hodgkin lymphoma. This move aims to improve the depth and durability of responses through enhanced cell therapy and may overcome tumor resistance to rituximab. The stock price fluctuated following this announcement. On February 2, ImmunityBio launched a chemotherapy-free CAR-NK cell therapy trial targeting indolent lymphoma. This news attracted market attention, leading to stock price fluctuations. On February 2, ImmunityBio emphasized in its press release the "durable complete responses" achieved in the first phase trial of its cell therapy and plans to add Anktiva in the second phase trial to further enhance efficacy. This news impacted the stock price. The U.S. stock market has seen increased volatility recently and requires attention. Moderna rose 0.31% in the night market. Based on recent key news: On February 4, OpenAI's CEO Altman stated that the company may seek partners or investments in AI drug discovery. This news may spark market expectations for potential collaborations for Moderna in the AI drug sector, driving its stock price up On February 3rd, Moderna's trading volume reached 4,254,325 shares, with the stock price falling by 1.24% to $43.52. The RSI indicator suggests that the stock may be approaching overbought territory, and analysts have downgraded its rating to neutral, with a target price of $34, leading to a cautious market outlook on its short-term performance. As of February 3rd, Moderna has 35 mRNA development candidates covering multiple therapeutic areas, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Despite the broad range of projects, analysts remain cautious about its short-term profitability, impacting stock price performance. The pharmaceutical industry faces policy changes and technological challenges